Non-Toxic, Biological Anti-Mold & Mildew Product Distribution Agreement Signed by Pegasus’ New Distributor in Mexico
SOURCE:
Pegasus Pharmaceuticals Inc.
2008-07-16 11:44:00
Non-Toxic, Biological Anti-Mold & Mildew Product Distribution Agreement Signed by Pegasus’ New Distributor in Mexico
PALM BEACH GARDENS, FL–(EMWNews – July 16, 2008) – Pegasus Pharmaceuticals (
Tenax Corporation of California to distribute and sell its new,
laboratory-proven, biological anti-mold and mildew product in Mexico.
Tenax Corporation, through its wholly owned subsidiary in Mexico, will
market the product under the name “Doctor Mongo™.” The Company has
recently completed its market research and the various packaging formats
and designs for the Doctor Mongo brand product launch. (Please refer to the
Company website www.pegasusbiosciences.com for photos of the product
packaging.) Tenex has an excellent track record of launching and
distributing new products in Mexico for over ten years. And not only has
it built up a rapport with the Mexican Government, it has established
working relationships and distribution infrastructures with a large range
of retailers such as HEB Stores, Home Depot, Costco, SORIANA and many more.
Tenax will focus on all retail, commercial and professional markets for
Doctor Mongo™ product sales in Mexico.
Recent independent laboratory tests have proven that Doctor Mongo™
represents a breakthrough in mold control technology. The product
demonstrated a remarkable 100% efficiency (0% mold growth) over a 100-day
period and far outperformed four other leading U.S. anti-mold products. The
product’s active ingredients are non-toxic, biodegradable and are naturally
occurring. Doctor Mongo™ represents a new era in anti-microbial,
anti-fungal protection because it not only removes black mold infestation,
it also cleans and disinfects surfaces, preventing further mold spore
growth in residential, commercial or institutional applications.
For more information, please contact Paul Davey, Investor Services:
778-389-0915 or email: [email protected], or contact Daniel P.
Kesonen, Chairman & CEO, Pegasus Pharmaceuticals, Inc. at (561) 626-9901.
Pegasus Pharmaceuticals adheres to the statutes and provisions of the Safe
Harbor Act.
| For more information, please contact: Paul Davey Investor Services: (778) 389-0915 [email protected] Daniel P. Kesonen |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
